MRX-2843 and Osimertinib for the Treatment of Advanced EGFR Mutant Non-small Cell Lung Cancer

This study tests a new drug called MRX-2843 combined with osimertinib (Tagrisso) for patients with advanced non-small cell lung cancer (NSCLC) that has a specific genetic mutation (EGFR mutation) that drives cancer growth. **You may be eligible if...** - You have confirmed metastatic non-small cell lung cancer with an EGFR mutation (in exons 19 or 21) - You are in reasonably good health (ECOG performance status 0–2) - For the expansion phase, you must have at least one measurable tumor **You may NOT be eligible if...** - You do not have an EGFR mutation - You are in poor general health - You have not received prior EGFR-targeted therapy (depending on cohort) Talk to your doctor to see if this trial is right for you.